What is Alnylam Pharmaceuticals's zilebesrian — interest expense?

Alnylam Pharmaceuticals (ALNY) reported zilebesrian — interest expense of $1.85M in Q1 2026.

How has Alnylam Pharmaceuticals's zilebesrian — interest expense changed year-over-year?

Alnylam Pharmaceuticals's zilebesrian — interest expense increased by 7.8% year-over-year, from $1.71M to $1.85M.

Zilebesrian — Interest Expense

Alnylam Pharmaceuticals Zilebesrian — Interest Expense increased by 7.8% to $1.85M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.8%, from $1.71M to $1.85M.

Analysis

StatementSegment

First reportedQ1 2025

Last reportedQ1 2026

Metric ID: alny_segment_zilebesrian_interest_expense

Historical Data

5 periods

	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$1.71M	$1.71M	$1.71M	$1.71M	$1.85M
QoQ Change	—	+0.0%	+0.0%	+0.0%	+7.8%
YoY Change	—	—	—	—	+7.8%

Range$1.71M – $1.85M

CAGR+7.8%

Avg YoY Growth+7.8%

Median YoY Growth+7.8%

Current Streak4+ quarters growth

Frequently Asked Questions

What is Alnylam Pharmaceuticals's zilebesrian — interest expense?: Alnylam Pharmaceuticals (ALNY) reported zilebesrian — interest expense of $1.85M in Q1 2026.
How has Alnylam Pharmaceuticals's zilebesrian — interest expense changed year-over-year?: Alnylam Pharmaceuticals's zilebesrian — interest expense increased by 7.8% year-over-year, from $1.71M to $1.85M.